Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels

Takeda Pharmaceutical’s oveporexton is designed to treat the root cause of narcolepsy. Statistically significant Phase 3 results for the twice daily pill were presented Monday during the World Sleep 2025 Congress in Singapore. The post Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels appeared first on MedCity…

Read More

Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt

Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF. The post Summit Lung…

Read More

Cuando deje este mundo, que sea de forma ecológica

Cada año, durante nuestras vacaciones familiares en Cape Cod, disfrutamos de todos los placeres clásicos del verano: escalar dunas, caminar por la playa, observar focas, comer ostras y leer los libros que nos habíamos propuesto durante todo el año. También hacer compras. Mi nieto quería unos juguetes pequeños. Mi hija aprovechó para llevarse varios rompecabezas…

Read More